Proceeds from the financing will be used to advance KYV-101, an autologous version of a novel clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties uniquely suited for use in B cell-driven autoimmune diseases such as lupus nephritis, systemic sclerosis, and inflammatory myopathies.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

740 Heinz Ave.
Berkeley, CA 94710
USA

Phone

Undisclosed

Website

www.kyvernatx.com

Email Address

[email protected]

Overview

We are a cell therapy company developing a new class of treatments and potential cures for serious autoimmune diseases. Autoimmune diseases result from a failure of the immune system to distinguish self from non-self, caused by autoreactive B cells and T cells attacking the body's own tissues.

Profile

Social Media

Kyverna Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Dominic Borie

Chief Scientific Officer

Jeffrey Greve

VP - General Counsel

Gregory Giotta

VP - Operations

Ryan Jones

Browse more venture capital transactions:

Prev: 2/2/2022: Kleoverse venture capital transaction
Next: 2/2/2022: Hometap venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to document every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary